Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Theo de Witte, Raphael Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo Sanz, Christof Scheid, Eric Solary, Peter Valent, Raffaela Greco, Isabel Sanchez-Ortega, Ibrahim Yakoub-Agha, Lisa Pleyer

Blood (2024) 143 (22): 2227–2244.

https://doi.org/10.1182/blood.2023023476

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Evangelos Terpos, Efstathios Kastritis, Argiris Symeonidis, Anastasia Pouli, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2023-173185

Published: 2023

Journal Articles

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Argiris Symeonidis, Anastasia Pouli, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Ioannis Ninos, Sosana Delimpasi, Eleftheria Hatzimichael, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6728.

https://doi.org/10.1182/blood-2023-173170

Published: 2023

Journal Articles

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Anthi Bouchla, Theodoros Loupis, Georgia Delikonstantinos, Frieda Kontsioti, Vassiliki Mpakou, Maria Dellatola, Maria Pagoni, Konstantinos Theodorakopoulos, Sotirios Papageorgiou, Argiris Symeonidis, Vassiliki Pappa

Blood (2022) 140 (Supplement 1): 6250–6251.

https://doi.org/10.1182/blood-2022-158980

Published: 2022

Journal Articles

Real-World Data on the Use of Luspatercept in Greek Patients with Transfusion Dependent Thalassemia

Blood (2022) 140 (Supplement 1): 8205–8207.

https://doi.org/10.1182/blood-2022-167675

Published: 2022

Journal Articles

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou

Blood (2022) 140 (Supplement 1): 9554–9556.

https://doi.org/10.1182/blood-2022-168627

Published: 2022

Journal Articles

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Christina-Nefeli Kontandreopoulou, Stavroula Syriopoulou, Panagiotis T Diamantopoulos, Nefeli Giannakopoulou, Dimitra Vlachopoulou, Panagiota Katsiampoura, Christos Stafylidis, Maria Dimou, Athanasios Galanopoulos, Sotirios Papageorgiou, Eleftheria Hatzimichael, Vassiliki Pappa, Kotsianidis Ioannis, Argiris Symeonidis, Panayiotis Panayiotidis, Nora-Athina Viniou

Blood (2022) 140 (Supplement 1): 6958–6959.

https://doi.org/10.1182/blood-2022-165870

Published: 2022

Journal Articles

The Transcription Factor ETS-1 Correlates with the Increased Age Associated B Cells in Patients with Acquired Aplastic Anemia

Elena E. Solomou, Antonis Kattamis, Argiris Symeonidis, Haroula Sirinian, Christina Salamaliki, Panagiotis T Diamantopoulos, Athanasios Galanopoulos, Maria D. Palasopoulou, Christina-Nefeli Kontandreopoulou, Nikolaos Giannakoulas, Nora-Athina Viniou, Stamatis-Nick Liossis, George Vassilopoulos

Blood (2022) 140 (Supplement 1): 481–482.

https://doi.org/10.1182/blood-2022-157696

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Blood (2022) 140 (Supplement 1): 9802–9803.

https://doi.org/10.1182/blood-2022-167716

Published: 2022

Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 9995–9997.

https://doi.org/10.1182/blood-2022-163092

Published: 2022

Journal Articles

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Blood (2022) 140 (Supplement 1): 7272–7274.

https://doi.org/10.1182/blood-2022-163483

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Sosana Delimpasi, Michele Cavo, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Roussou, Despina Fotiou, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Alexandros Leonidakis, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 2729.

https://doi.org/10.1182/blood-2021-153075

Published: 2021

Journal Articles

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Alexandros Leonidakis, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2021-153082

Published: 2021

Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Older Patients

Maria-Victoria Mateos, Pawel J. Robak, Laura Rosiñol, Argiris Symeonidis, Pieter Sonneveld, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek

Blood (2021) 138 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2021-147005

Published: 2021

Journal Articles

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Blood (2021) 138 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2021-146907

Published: 2021

Journal Articles

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Blood (2021) 138 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2021-149630

Published: 2021

Journal Articles

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Evangelos Terpos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Ioannis Ntanasis-Stathopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2021-152385

Published: 2021

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Blood (2021) 138 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2021-150322

Published: 2021

Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades

Blood (2021) 138 (Supplement 1): 242.

https://doi.org/10.1182/blood-2021-146154

Published: 2021

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

NARROW

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Real-World Data on the Use of Luspatercept in Greek Patients with Transfusion Dependent Thalassemia

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

The Transcription Factor ETS-1 Correlates with the Increased Age Associated B Cells in Patients with Acquired Aplastic Anemia

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

OCEAN (OP-103): Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Older Patients

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only